Diagnostics group DiaSorin's nine-month adjusted core profit up 6%
Nov 5 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnostic segment. ($1 = 0.9169 euros) (Reporting by Michela Stasio in Gdansk Editing by David Goodman ) ((michela.stasio@thomsonreuters.com))
Recent news on Diasorin
See all newsEquita upgrades Diasorin, sees 'solid' Q3
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21